BBR Partners’s AstraZeneca AZN Stock Holding History

BBR Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,376	Closed	-$237K	–	161
2019 Q4	$237K	Buy	+2,376	New	+$224K	0.03%	170

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BBR Partners's AZN Position: Q1 2020 in Review

BBR Partners sold out of AstraZeneca (AZN) in Q1 2020, closing a stake of 2,376 shares — an estimated $237K sold.

BBR Partners first reported a position in AZN in Q4 2019 and held it in 1 quarter. The position peaked at $237K in Q4 2019. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

BBR Partners reported no remaining AstraZeneca position as of Q1 2020 after selling out during the quarter.
BBR Partners sold 2,376 AstraZeneca shares in Q1 2020, an estimated $237K.
BBR Partners first reported a position in AstraZeneca in Q4 2019 and held it in 1 quarter.
BBR Partners's AstraZeneca position peaked at $237K in Q4 2019.
603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on BBR Partners's 13F filing for Q1 2020, filed 14 May 2020.